Because taste
matters.
Expand your portfolio with patient-centric solutions. Drive value by elevating oral delivery through our proprietary platforms.
The Waterless Advantage
Medication that adapts to the patient's life, not the other way around. Pioneering convenience through clinical excellence.
On-the-Go Freedom
Eliminate the need for water, allowing patients to take medication anywhere, anytime, with complete discretion.
Dysphagia Solutions
Empowering geriatric and pediatric patients who struggle with swallowing traditional solid dosage forms.
Unmatched Compliance
Superior organoleptic profiles directly correlate with improved patient adherence and therapeutic outcomes.
The Art of Compliance
REDEFINING THE
PATIENT EXPERIENCE
European Patent Protected Technology
Market Dominance for Licensees
Targeting R&D Directors and Business Development leaders looking for significant PLM advantages.
-
Product Lifecycle Management
Extend patent life cycles by introducing improved formulations of existing APIs.
-
Demographic Expansion
Capture pediatric and geriatric markets with patient-friendly formats.
-
Premium Brand Positioning
Differentiate your brand in crowded markets through a superior sensory experience.
Strategic & Scientific Leadership
Two pillars of excellence: business vision and scientific rigor driving pharmaceutical innovation.
Francesc Agell
CEO of BPS Synergies
Redefining the Pharmaceutical Experience through Technical Excellence
With a career spanning over three decades at the forefront of the chemical and pharmaceutical industries, Francesc Agell does more than lead BPS Synergies—he is driving a paradigm shift in oral drug delivery.
A Vision Forged Through Decades of Expertise
Over 30 years of experience in the promotion and commercialization of synthesis intermediates, Active Pharmaceutical Ingredients (APIs), and drug licensing have provided Francesc with a unique, 360-degree view of the industry. This deep immersion in the value chain—from the raw molecule to the final license agreement—led him to identify critical systemic gaps:
- Pinpointing Market Gaps: He recognized that while the industry excelled at molecular efficacy, it often overlooked the "last mile" of medicine: the patient experience.
- Addressing the "Pain": He observed how breakthrough therapeutic developments often struggled with patient adherence due to sensory barriers, particularly in pediatric and geriatric populations.
- Regulatory Mastery: His extensive knowledge of regulated markets ensures that innovation at BPS Synergies is not only disruptive but also meets the most stringent global safety and quality standards.
BPS Synergies: The Strategic Solution
Under his leadership, BPS Synergies has evolved from a supplier into a strategic innovation partner. Francesc has channeled his expertise into solving one of the most persistent challenges in oral administration: the science of taste.
"True innovation is not just about what we cure, but about how we ensure the cure reaches the patient in an effective, humane, and sustainable way."
Through the development of proprietary patents focused on taste-masking, Francesc and his team have unlocked solutions that:
- Mask bitter or metallic notes in complex APIs without compromising bioavailability.
- Drastically improve therapeutic adherence, reducing treatment abandonment caused by organoleptic rejection.
- Provide a competitive edge for pharmaceutical companies, allowing them to differentiate their portfolios in saturated markets through tangible, patented advantages.
Authority and Commitment
Francesc Agell embodies the CEO who speaks the language of both the laboratory and the boardroom. His authority is built on a career dedicated to understanding the industry's shortcomings and methodically engineering the solutions the market has long demanded.
At BPS Synergies, his mission is clear: To set a new global standard for oral drug administration through the science of taste.
Dr. Jaume Saurí
Scientific Director
Scientific Leadership and Innovation
At BioPharma Synergies, our technology is supported by deep industrial experience and academic rigor. Dr. Jaume Saurí, holding dual degrees in Pharmacy and Biochemistry and a Cum Laude Doctorate, leads the development of our most advanced pharmaceutical solutions.
Industrial Expertise: From R&D to Production Plant
Dr. Saurí brings over 15 years of direct experience in pharmaceutical industry giants such as Almirall and Recipharm. His trajectory is defined by a comprehensive vision of medicine, spanning from conceptual design in the laboratory to industrial scale-up and process validation.
- Galenic Development: Has led the reformulation and technology transfer of multiple pharmaceutical forms, including tablets, capsules, solutions, and inhalation powders.
- Quality and Registration: Holds solid postgraduate training in Quality (GMP/GLP) and Pharmaceutical Registration, ensuring that every innovation meets the most demanding regulatory standards.
Specialization in Orodispersible Technologies
Currently, Dr. Saurí focuses his research on the design of new orodispersible formulations (ODT). His work is fundamental to BPS's mission: developing medicines that dissolve rapidly in the mouth, improving the masking of bitter active ingredients and facilitating therapeutic adherence in pediatric, geriatric, or dysphagia patients.
Academic Excellence and Publications
Doctorate from the University of Barcelona with a unanimous Cum Laude qualification, his thesis focused on controlled release systems and direct compression technologies. His contribution to pharmaceutical science is evidenced in high-impact international publications:
Featured Scientific Publications:
- Formulation and characterization of mucoadhesive controlled release matrix tablets of captopril. Journal of Drug Delivery Science and Technology (2017).
- Relationships between surface free energy, surface texture parameters and controlled drug release in hydrophilic matrices. International Journal of Pharmaceutics (2015).
- Quality by design approach to understand the physicochemical phenomena involved in controlled release. International Journal of Pharmaceutics (2014).
- The use of the SeDeM diagram expert system for the formulation of Captopril SR matrix tablets by direct compression. International Journal of Pharmaceutics (2014).
With Dr. Saurí, BioPharma Synergies ensures that every project is developed under the principles of Quality by Design, merging materials science with the real needs of patients.
Revolutionizing Oral Delivery
The Synergy of Instant Taste Masking and Advanced Rheological Engineering
Three pillars of pharmaceutical innovation that redefine patient experience and manufacturing excellence.
Sensory Engineering
The Ternary Synergy: Mastering Bitterness Without Barriers
Our proprietary sensory modulation technology delivers instant taste masking without affecting drug release, ensuring optimal palatability from the first moment of administration.
-
Non-Occlusive Mechanism The technology elevates the bitter taste detection threshold through direct sensory interference in the oral cavity.
-
Neutralization of Critical APIs Proven efficacy on highly bitter active ingredients such as triptans and antihistamines.
-
Superior Sensory Profile Dramatically improves patient experience by eliminating metallic or bitter aftertaste immediately.
Manufacturing Efficiency
Operational Excellence: Direct Mixing and Superior Flowability
Designed for production and galenic managers, focusing on the process advantages of orodispersible powders.
-
Process Simplification The technology enables Direct Mixing, eliminating costly steps such as wet granulation or fluid bed coating.
-
Optimized Rheological Parameters Formulations exhibit excellent Hausner Ratio (1.04-1.14) and Compressibility Index of 9-12%, ensuring precise dosing on high-speed lines.
-
Industrial Stability Flow properties remain unchanged during storage, ensuring batch-to-batch reproducibility.
Therapeutic Performance
Clinical Advantage: Ultra-Fast Dissolution for Accelerated Bioavailability
Direct impact on the patient and clinical value of the final product.
-
Dissolution Kinetics Ultra-rapid dissolution in the oral cavity, typically in less than 15 to 30 seconds, without the need for water.
-
Optimized Absorption With no polymeric barriers, the drug is immediately available for absorption, critical in rescue treatments like migraine.
-
Format Versatility Technology adaptable for both powder stick packs and orodispersible tablets, covering a broad spectrum of pathologies.
Delivery Systems
Versatile formats engineered for manufacturing scalability and patient delight.
Chewable Tablets
Soft-textured, high-load capacity tablets with immediate release profiles.
Stick Pack Powder
Direct-to-mouth powder with instant melt-in-mouth technology.
Orodispersible Tablets (ODT)
Fast-dissolving tablets that melt in seconds without water.
Clinical Superiority
Beyond convenience. Evidence-based clinical advantages of waterless delivery systems.
Enhanced Bioavailability
Pre-solubilized matrices in ODFs and ODTs facilitate rapid transmucosal absorption, bypassing first-pass metabolism for faster onset of action.
100% Dosing Accuracy
Precision-manufactured units eliminate the variability of liquid measuring, ensuring patients receive the exact therapeutic dose every time.
Adherence Security
Eliminating the water barrier significantly reduces "pill burden" resistance, critical for pediatric, geriatric, and psychiatric adherence rates.
Aspiration Safety
Fast-dissolving formats mitigate choking risks (dysphagia), offering a safer alternative to traditional solids for compromised swallowing reflexes.
European Patent Protection
Exclusive rights for formulation, production, and commercialization across major markets.
Territories
Western & Northern Europe
Eastern & Central Europe
South & Mediterranean
Key Technological Advantages
Significantly outperforms current competitors
Tailored flavor for every region and audience
Superior to traditional paracetamol tablets
Industrial scalability guaranteed
Protected Formats
-
Orodispersible Powder Core ternary composition allowing rapid dissolution without water.
-
Stick Pack (Claim 13) Protected commercial presentation for patient convenience.
-
Compressed Tablet (Claim 14) Direct compression of the powder into solid dosage forms.
European Patent Protected Technology
Contact
Visit us in the heart of Barcelona's innovation ecosystem
BPsynergies S.L.
Gran Vía de Carles III, 41, Esol. 2ª
08028 Barcelona, Spain
Monday - Friday: 9:00 - 18:00